株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

MediPoint:大腸癌の対外診断用スクリーニング検査市場 - 現在・将来の市場参入企業

MediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players

発行 GlobalData 商品コード 286304
出版日 ページ情報 英文 212 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
MediPoint:大腸癌の対外診断用スクリーニング検査市場 - 現在・将来の市場参入企業 MediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players
出版日: 2013年08月31日 ページ情報: 英文 212 Pages
概要

当レポートでは、世界各国の大腸癌(CRC)の対外診断用スクリーニング検査の市場について分析し、全体的な市場の構造や動向、市場全体および分野別の競争構造、現在開発中の製品の治験進行状況、現在活動中または今後参入予定の主要企業の概要(プロファイル・製品構成・SWOT分析)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 競争分析

  • 概要
  • 便潜血反応検査
    • グアヤク法検査
    • 側方流動式免疫学的便潜血検査
    • リーダー(読取装置)
    • 免疫便潜血向けELISA検査
    • 免疫便潜血癒着検査
  • 大腸癌のDNAスクリーニング検査
    • パネルDNA検査
    • メチル化遺伝子検査
  • その他のバイオマーカー検査
    • 概要
    • 腫瘍M2-PK便検査/2-in-1急速検査
    • トランスフェリン検査

第4章 パイプライン製品

  • 概要
  • 開発段階別のパイプライン
  • パイプライン製品のプロファイル(全17種類)

第5章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • Abbott Molecular
    • Alere
    • Beckman Coulter
    • Biomarcare Technologies
    • Companion Dx
    • 栄研化学
    • Epigenomics
    • Exact Sciences
    • ExiQon
    • 富士レビオ(みらかホールディングス)
    • GeneNews
    • GenomicTree
    • Immunostics
    • 協和メデックス
    • MDx Health(旧OncoMethylome)
    • Merck Millipore
    • Metabiomics
    • Mode Diagnostics
    • Oncocyte (Bio Time)
    • Quest Diagnostics
    • R-Biopharm
    • Randox Laboratories
    • ScheBo Biotech
    • SciMarket Technologies
    • Siemens Healthcare
    • Signature Diagnostics
    • シスメックス
    • Veda Lab

第6章 付録

図表一覧

目次
Product Code: GDME1013FPR

GlobalData has released its medical device report, "MediPoint: In-Vitro Colorectal Cancer Screening Tests - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the steadily growing In-Vitro Colorectal Cancer Screening Tests Market. Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.

Scope

  • Investigation of current and future market competition for In-Vitro Colorectal Cancer Screening Tests.
  • Competitor assessment including device approval analysis.
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as interventional cardiologists and radiologists already using In-Vitro Colorectal Cancer Screening Tests in clinical practice.

Reasons to buy

  • Gain a high level view of the trends shaping and driving the In-Vitro Colorectal Cancer Screening Tests market for coronary applications and peripheral applications in the lower extremity.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Competitive Assessment

  • 3.1. Overview
  • 3.2. Fecal Occult Blood Tests
    • 3.2.1. Guaiac Fecal Occult Blood Stool Tests
    • 3.2.2. Lateral Flow Immuno-Fecal Occult Blood Tests
    • 3.2.3. Readers
    • 3.2.4. Immuno-FOB Test ELISA
    • 3.2.5. Immuno-FOB Agglutination Tests
  • 3.3. CRC DNA Screening Tests
    • 3.3.1. Panel DNA Tests
    • 3.3.2. Methylated Gene Testing
  • 3.4. Other Biomarker Tests
    • 3.4.1. Overview
    • 3.4.2. Tumor M2-PK Stool Test/2-in-1 Quick Test
    • 3.4.3. Transferrin Assays

4. Pipeline Products

  • 4.1. Overview
  • 4.2. Pipeline by Phases in Development
  • 4.3. Pipeline Product Profiles
    • 4.3.1. BST1 CRC Assay
    • 4.3.2. Cologic
    • 4.3.3. ColoGuard
    • 4.3.4. Colon Cancer BEC Test
    • 4.3.5. Colon MarCare Plex
    • 4.3.6. Colox
    • 4.3.7. CRC Bacterial Signature Assay
    • 4.3.8. CRC Breath Test
    • 4.3.9. Epi proColon
    • 4.3.10. ExiQon MicroRNA Test
    • 4.3.11. Gemini CRC Biomarker Assay
    • 4.3.12. GenomicTree Methylated DNA Test
    • 4.3.13. Measure Fecal Occult Blood Test
    • 4.3.14. Metabiomics CRC Test
    • 4.3.15. MiR-21 Test
    • 4.3.16. Oncolite CR
    • 4.3.17. PanC-Dx

5. Current and Future Players

  • 5.1. Overview
  • 5.2. Trends in Corporate Strategy
  • 5.3. Company Profiles
    • 5.3.1. Abbott Molecular
    • 5.3.2. Alere
    • 5.3.3. Beckman Coulter
    • 5.3.4. Biomarcare Technologies
    • 5.3.5. Companion Dx
    • 5.3.6. Eiken Chemical
    • 5.3.7. Epigenomics
    • 5.3.8. Exact Sciences
    • 5.3.9. ExiQon
    • 5.3.10. Fujirebio (Miraca Holdings)
    • 5.3.11. GeneNews
    • 5.3.12. GenomicTree
    • 5.3.13. Immunostics
    • 5.3.14. Kyowa Medex
    • 5.3.15. MDx Health (was OncoMethylome)
    • 5.3.16. Merck Millipore
    • 5.3.17. Metabiomics
    • 5.3.18. Mode Diagnostics
    • 5.3.19. Oncocyte (Bio Time)
    • 5.3.20. Quest Diagnostics
    • 5.3.21. R-Biopharm
    • 5.3.22. Randox Laboratories
    • 5.3.23. ScheBo Biotech
    • 5.3.24. SciMarket Technologies
    • 5.3.25. Siemens Healthcare
    • 5.3.26. Signature Diagnostics
    • 5.3.27. Sysmex
    • 5.3.28. Veda Lab

6. Appendix

  • 6.1. Abbreviations
  • 6.2. Bibliography
  • 6.3. Research Methodology
    • 6.3.1. Coverage
    • 6.3.2. Secondary Research
  • 6.4. Physicians and Specialists Included in this Study
  • 6.5. Primary Research
  • 6.6. About the Authors
    • 6.6.1. Analysts
    • 6.6.2. Global Head of Healthcare
  • 6.7. About GlobalData
  • 6.8. Disclaimer

List of Tables

  • Table 1: CRC Screening Test Segmentation
  • Table 2: Guaiac Fecal Occult Blood Tests Product Profile
  • Table 3: Guaiac FOB Test SWOT Analysis, 2013
  • Table 4: Immuno-FOB Tests
  • Table 5: Product Profile - Lateral Flow Immunochemical Fecal Occult Blood Tests
  • Table 6: Lateral Flow Immunochemical Fecal Occult Blood Tests SWOT Analysis, 2013
  • Table 7: Product Profile - Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers)
  • Table 8: Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) SWOT Analysis, 2013
  • Table 9: Fecal Occult Blood ELISA Products
  • Table 10: Product Profile - Fecal Occult Blood ELISA
  • Table 11: Immuno-FOB Test ELISA SWOT Analysis, 2013
  • Table 12: Commercially Available Immuno-FOB Agglutination Test Systems
  • Table 13: Product Profile - Immuno-FOB Agglutination Tests
  • Table 14: Immuno-FOB Agglutination Tests SWOT Analysis, 2013
  • Table 15: Key Mutations Associated with CRC
  • Table 16: Key Stages of PCR Gene Test
  • Table 17: Product Profile - PreGen Plus
  • Table 18: PreGen Plus SWOT Analysis, 2013
  • Table 19: Product Profile - K-RAS, B-RAF, PIK3CA Array
  • Table 20: K-RAS, B-RAF, PIK3CA Array SWOT Analysis, 2013
  • Table 21: Product Profile - Colonsentry
  • Table 22: Colonsentry SWOT Analysis, 2013
  • Table 23: Product Profile - Detector C 2.0
  • Table 24: Detector C SWOT Analysis, 2013
  • Table 25: Product Profile - ColoSure
  • Table 26: ColoSure SWOT Analysis, 2013
  • Table 27: Product Profile - MS9
  • Table 28: MS9 SWOT Analysis, 2013
  • Table 29: Septin-9 CRC Screening Marketed Laboratory-Developed Tests
  • Table 30: Product Profile - ColoVantage/Septin-9
  • Table 31: ColoVantage/Septin-9 SWOT Analysis, 2013
  • Table 32: Product Profile - Tumor M2-PK Stool Test/2-in-1 Quick Test
  • Table 33: Tumor M2-PK Stool Test/2-in-1 Quick Test SWOT Analysis, 2013
  • Table 34: Product Profile - Transferrin Assays
  • Table 35: Transferrin Assays SWOT Analysis, 2013
  • Table 36: CRC Screening Tests Pipeline, 2012
  • Table 37: Product Profile - BST1 CRC Assay
  • Table 38: BST1 CRC Assay SWOT Analysis, 2013
  • Table 39: Product Profile - Cologic
  • Table 40: Cologic SWOT Analysis, 2013
  • Table 41: Product Profile - ColoGuard
  • Table 42: ColoGuard SWOT Analysis, 2013
  • Table 43: Product Profile - Colon Cancer BEC Test
  • Table 44: Colon Cancer BEC Test SWOT Analysis, 2013
  • Table 45: Product Profile - Colon MarCare Plex
  • Table 46: Colon MarCare Plex SWOT Analysis, 2013
  • Table 47: Product Profile - Colox
  • Table 48: Colox SWOT Analysis, 2013
  • Table 49: Product Profile - CRC Bacterial Signature Assay
  • Table 50: CRC Bacterial Signature Assay SWOT Analysis, 2013
  • Table 51: Product Profile - CRC Breath Test
  • Table 52: CRC Breath Test SWOT Analysis, 2013
  • Table 53: Product Profile - Epi proColon
  • Table 54: Epi proColon Clinical Trials
  • Table 55: Epi proColon SWOT Analysis, 2013
  • Table 56: ExiQon MicroRNA Sensitivity and Specificity
  • Table 57: Product Profile - ExiQon microRNA Test
  • Table 58: ExiQon microRNA Test SWOT Analysis, 2013
  • Table 59: Product Profile - Gemini CRC Biomarker Assay
  • Table 60: Gemini CRC Biomarker Assay SWOT Analysis, 2013
  • Table 61: Product Profile - GenomicTree Methylated DNA Test
  • Table 62: GenomicTree Methylated DNA Test SWOT Analysis, 2013
  • Table 63: Product Profile - Measure
  • Table 64: Measure SWOT Analysis, 2013
  • Table 65: Product Profile - Metabiomics CRC Test
  • Table 66: Metabiomics CRC Test SWOT Analysis, 2013
  • Table 67: Product Profile - miR-21 Test
  • Table 68: miR-21 Test SWOT Analysis, 2013
  • Table 69: Product Profile - Oncolite-CR
  • Table 70: Oncolite-CR SWOT Analysis, 2013
  • Table 71: Product Profile - PanC-Dx
  • Table 72: PanC-Dx SWOT Analysis, 2013
  • Table 73: Company Profile - Abbott Molecular
  • Table 74: Abbott Molecular SWOT Analysis, 2013
  • Table 75: Company Profile - Alere
  • Table 76: Alere SWOT Analysis, 2013
  • Table 77: Company Profile - Beckman Coulter
  • Table 78: Beckman Coulter SWOT Analysis, 2013
  • Table 79: Company Profile - Biomarcare Technologies
  • Table 80: Biomarcare Technologies SWOT Analysis, 2013
  • Table 81: Company Profile - Companion Dx
  • Table 82: Companion Dx SWOT Analysis, 2013
  • Table 83: Company Profile - Eiken Chemical
  • Table 84: Eiken Chemical SWOT Analysis, 2013
  • Table 85: Company Profile - Epigenomics
  • Table 86: Epigenomics SWOT Analysis, 2013
  • Table 87: Company Profile - Exact Sciences
  • Table 88: Exact Sciences SWOT Analysis, 2013
  • Table 89: Company Profile - ExiQon
  • Table 90: ExiQon SWOT Analysis, 2013
  • Table 91: Company Profile - Fujirebio (Miraca Holdings)
  • Table 92: Fujirebio SWOT Analysis, 2013
  • Table 93: Company Profile - GeneNews
  • Table 94: GeneNews SWOT Analysis, 2013
  • Table 95: Company Profile - GenomicTree
  • Table 96: GenomicTree SWOT Analysis, 2013
  • Table 97: Company Profile - Immunostics
  • Table 98: Immunostics SWOT Analysis, 2013
  • Table 99: Company Profile - Kyowa Medex (Kyowa Hakko Kirin Group)
  • Table 100: Kyowa Medex SWOT Analysis, 2013
  • Table 101: Company Profile - MDx Health
  • Table 102: MDx Health SWOT Analysis, 2013
  • Table 103: Company Profile - Merck Millipore
  • Table 104: Merck Millipore SWOT Analysis, 2013
  • Table 105: Company Profile - Metabiomics
  • Table 106: Metabiomics SWOT Analysis, 2013
  • Table 107: Company Profile - Mode Diagnostics
  • Table 108: Mode Diagnostics SWOT Analysis, 2013
  • Table 109: Company Profile - Oncocyte (Bio Time)
  • Table 110: Oncocyte (Bio Time) SWOT Analysis, 2013
  • Table 111: Company Profile - Quest Diagnostics
  • Table 112: Quest Diagnostics SWOT Analysis, 2013
  • Table 113: Company Profile - R-Biopharm
  • Table 114: R-Biopharm SWOT Analysis, 2013
  • Table 115: Company Profile - Randox Laboratories
  • Table 116: Randox Laboratories SWOT Analysis, 2013
  • Table 117: Company Profile - ScheBo Biotech
  • Table 118: Schebo Biotech SWOT Analysis, 2013
  • Table 119: Company Profile - SciMarket Technologies
  • Table 120: SciMarket Technologies SWOT Analysis, 2013
  • Table 121: Company Profile - Siemens Healthcare
  • Table 122: Siemens Healthcare SWOT Analysis, 2013
  • Table 123: Company Profile - Signature Diagnostics
  • Table 124: Signature Diagnostics SWOT Analysis, 2013
  • Table 125: Company Profile - Sysmex
  • Table 126: Sysmex SWOT Analysis, 2013
  • Table 127: Company Profile - Veda Lab
  • Table 128: Veda Lab SWOT Analysis, 2013

List of Figures

  • Figure 1: Example of a Guaiac Fecal Occult Blood Card: Immunostics Hema-Screen
  • Figure 2: Fecal Occult Blood Test Lateral Flow Device Architecture
  • Figure 3: Biohit Colonview (example of immuno-FOB test)
  • Figure 4: Beckman Coulter Hemoccult-ICT (example of immuno-FOB test)
  • Figure 5: Veda Labs Easy Reader Immuno-FOB Test LFD Reader
  • Figure 6: OC-Hemodia Agglutination FOB Test (manually performed)
  • Figure 7: OC-Sensor/Diana FOB Test Sample Cartridge
  • Figure 8: OC-Sensor/Diana FOB Test Instrument
  • Figure 9: Fujirebio HemSp/MagStream HT Magnetic Agglutination Reaction
  • Figure 10: Sentinel Diagnostic Sentifob Instrument
  • Figure 11: Alere CI5 NS-Plus Instrument
  • Figure 12: Orion Diagnostics Quikread FOB Test and Instrument
  • Figure 13: Basic PCR Process
  • Figure 14: MS9 PCR Response Curve
  • Figure 15: Proposed ColoGuard Patient Stool Sample Collection Kit
  • Figure 16: Exact Sciences Automated Sample Processing WorkStation
  • Figure 17: Colox Kit Contents
  • Figure 18: Measure Fecal Occult Blood Test
  • Figure 19: PanC-Dx Multiplex Detection of CRC-specific Biomarker
Back to Top